Latest news with #Lancaster
Yahoo
17 hours ago
- Business
- Yahoo
Direct Wire Expands Copper Capabilities with 12.5mm OFE Rod Production and ISO 9001:2015 Certification
LANCASTER, Pa., July 24, 2025 /PRNewswire/ -- Direct Wire, a leading force in the wire and cable industry, proudly announces two major milestones at its state-of-the-art oxygen-free copper rod mill: the capability to produce 12.5mm oxygen-free electronic (OFE) copper rod and the achievement of ISO 9001:2015 certification, officially granted in March 2025. These advancements underscore Direct Wire's continued investment in precision, quality, and customer-focused innovation—further positioning the company as a trusted partner in the copper supply chain. Expanding Capabilities to Meet Market Demand With the successful introduction of 12.5mm OFE copper rod production, Direct Wire expands its range of premium copper products to meet the needs of high-spec applications across industries including electrical, aerospace, medical, and high-frequency electronics. This new diameter offering complements the mill's existing product portfolio and reinforces Direct Wire's ability to support custom and large-scale copper initiatives. "Our 12.5mm OFE rod gives customers more options in designing and building systems that demand the highest conductivity and purity," said Anthony Catoia, Director of Business Development for Direct Wire's Copper Division. "It's another example of how we're listening to our customers and responding with scalable, high-performance solutions." Quality You Can Trust: ISO 9001:2015 Certified Direct Wire's copper rod mill achieved ISO 9001:2015 certification in March 2025, a globally recognized standard for quality management systems. This certification validates the company's commitment to delivering consistent, high-quality products and maintaining continuous improvement practices across all aspects of production. "Being ISO 9001:2015 certified reinforces our commitment to quality at every level of our operations," said Greg Testa, Chief Revenue Officer at Direct Wire. "It demonstrates that our team is aligned, our systems are disciplined, and our customers can trust the excellence built into every copper product we deliver." Innovation Rooted in Service Direct Wire's copper upcasting process and vertically integrated production capabilities offer customers a unique combination of supply chain stability, product customization, and service reliability. The addition of 12.5mm OFE rod and the ISO certification reinforce the company's mission to lead with innovation—while remaining grounded in the principles that have defined "The Direct Difference" for over 47 years: Service, Technology, and People. As Direct Wire continues to grow, these latest advancements serve as key building blocks in supporting mission-critical industries with American-made copper products that meet the highest expectations for performance, reliability, and traceability. For more information on Direct Wire and our new copper rod mill facility, visit About Direct Wire Direct Wire has been a trusted name in the wire and cable industry for over 47 years, providing innovative, high-quality solutions to a diverse range of industries. With a steadfast commitment to customer service, technology, and employee development, Direct Wire continues to lead the industry with cutting-edge products and a dedication to excellence. Media Contact: Justin DahlMarketing Communications ManagerDirect Wire484-220-4628jdahl@ View original content to download multimedia: SOURCE Direct Wire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
17 hours ago
- Health
- Medscape
MCED Tests in Primary Care: Proceed With Caution
Hi, everyone. I'm Dr Kenny Lin. I am a family physician and associate director of the Lancaster General Hospital Family Medicine Residency, and I blog at Common Sense Family Doctor. Kenneth W. Lin, MD, MPH In the past decade or so that I have been giving lectures on cancer screening at family medicine review courses, not much has changed. We screen for breast, cervical, and colorectal cancer in large numbers of people. We screen for lung cancer in current or past smokers over 50 years of age with at least a 20 pack-year history. We discuss the potential benefits and harms of screening for prostate cancer with older males. But these five cancer types represent a distinct minority of cancers. A 2022 study estimated that only 1 in 7 diagnosed cancer cases in the United States are caught by any of these screening tests, and 57% of cancers have no recommended screening tests, meaning that they are usually not detected until advanced stages. For the past few years, Grail has been selling a blood test that aims to fill the early detection gap by detecting cell-free DNA signals associated with cancer. At $949 per test, the Galleri test is advertised as being able to detect more than 50 cancer types in adults aged 50 years or older. Other companies are developing similar tests. If they haven't already, family physicians will soon be asked to order multicancer early detection (MCED) tests for patients or act on their results. So, what do we know about their benefits and harms? And what remains uncertain? A systematic review published in May 2025 by the Agency for Healthcare Research and Quality found that the evidence for MCED tests consists mostly of diagnostic accuracy studies with suboptimal designs. A few prospective studies have shown that the tests are highly specific but have relatively low sensitivity for early-stage cancers. There is little data on harms such as false alarms, incidental findings, and unnecessary diagnostic procedures and treatments; in one study, patient-reported anxiety associated with a positive MCED result was small and returned to baseline by 12 months, regardless of whether cancer was confirmed. To be effective, MCED tests must accurately detect cancer in asymptomatic people at stages early enough to decrease harm (by subjecting patients to less toxic cancer therapy) or increase benefits (by allowing patients to live longer or better). Already under-resourced primary care practices would need to develop new workflows to work up patients with positive tests and determine when to refer them to oncologists. In a JAMA Internal Medicine Special Communication, screening experts argued that since MCED screening 'would entail tremendous costs and potentially substantial harms", it should not be implemented until a randomized trial reports it reduces all-cause mortality. Others feel that a trial showing fewer cancer-related deaths, such as one being planned by the National Cancer Institute, would be sufficient. An ongoing trial of Galleri in more than 140,000 UK National Health Service patients expects to report effects on cancer stage-shift (a reduction in late stage cancer diagnoses) as early as next year, though it appears to have failed to meet criteria for early indications of benefit. Recognizing that diffusion of MCED tests into practice is outpacing the evidence, the American Cancer Society published a consensus statement to guide primary care clinicians. Important points include communicating uncertainty about benefits and harms, emphasizing that patients with negative results should continue to have all screenings recommended by the US Preventive Services Task Force, and first evaluating patients with positive results for cancer at the predicted tissue of origin (eg, mammography for breast cancer), then ordering total body PET-CT scans if the tissue of origin is unknown or the initial workup is unrevealing.
Daily Mail
2 days ago
- Daily Mail
Twisted mind of jealous doctor who removed his wife's eye in 'Jigsaw Murder' and changed criminal cases forever
In the new episode of Daily Mail podcast - The Psychology of a Serial Killer, forensic psychiatrist Dr Andrew Johns and police surgeon Dr Harry Brujnes revisit a case that shocked 1930s Britain but has since been largely forgotten. The podcast examines history's most notorious medical murderers - those who pervert their positions of trust as doctors or nurses to prey on the public. The latest episode, released today focuses on the 1935 murders of Dr Buck Ruxton, a man so clinical in the disposal of his victims' bodies that the case broke ground in the fledgling field of forensic science. Listen to The Psychology of a Serial Killer below or by clicking here. In the latest episode of The Psychology of a Serial Killer, forensic psychiatrist Dr Andrew Johns (left) and police surgeon Dr Harry Brujnes (right) revisit a case that shocked 1930s Britain but has since been largely forgotten. Listen here. The Dastardly Deeds of Dr Buck Ruxton Buck Ruxton was born in Mumbai, India in 1899. After qualifying as a doctor at the University of Bombay in 1922, Ruxton left his wife and child to set up a practice in Lancaster, northwest England. Originally named Bukhtyar Hakim, the young doctor chose the name Buck Ruxton upon arriving to Britain. By 1930, Ruxton had established himself in Lancaster and had begun a common law marriage with Isabella Kerr, a local woman. 'He was known to be a respected and compassionate doctor,' Dr Harry Brujnes told The Psychology of a Serial Killer podcast. 'Ruxton had three children with Isabella, and it appears his reputation and social standing in the community were very important to him.' Behind closed doors, Ruxton was vicious to his wife. Police were repeatedly called to domestic violence incidents, driven by his obsessive belief that Isabella was being unfaithful. In September 1935, the paranoia erupted. Ruxton instigated what became known as the jigsaw murders, due to how brutally mutilated his victims were. 'He strangled and repeatedly stabbed his wife to death', Dr Andrew Johns said. 'At the same time, he bludgeoned the housemaid, Mary Rogerson, as she had witnessed the event. 'Fifteen days later, the multiple, mutilated remains of the two bodies were found under a bridge near Moffat, Scotland. 'Autopsies confirmed that the bodies had been brutalised. The eyes, ears, lips, teeth and fingernails of the victims were clinically excised to make identification difficult.' 'There are parallels to Jack the Ripper here', Dr Harry Brujnes commented. 'Ruxton didn't just murder, he clinically and surgically dissected. He was clearly somebody with extensive anatomical knowledge. 'It's a horrific thought: one day, this woman is your wife and the next, you are cutting out her eyes.' Police already knew Ruxton well - he had made repeated tearful visits to the station, ranting about his wife's alleged affairs, claiming she had run-off with a lover. A speculative search of Ruxton's home revealed damning evidence - bloodstains on the stairs, in the bathroom, and throughout the house. He was arrested immediately. However, the bodies still couldn't be identified due to the doctor's surgical precision - threatening to derail any potential prosecution. Investigators employed the novel strategy of X-raying the skull of one of the bodies and superimposing it on a photograph of Isabella to confirm a match. The Ruxton case pioneered what is now known as forensic anthropology in criminal investigations. Dr Andrew Johns explained what happened next: 'The Trial opened in March 1936 at Manchester High Court – the prosecution called numerous witnesses to support the case that inflamed by jealousy, Ruxton had committed two murders. 'The sole witness to testify on behalf of the defence was Ruxton himself. He conducted himself poorly on the stand, prone to hysterical sobbing and rambling statements. 'The jury would deliberate for just one hour before returning a guilty verdict. 'Despite a petition from Lancaster residents containing 10,000 signatures, which urged clemency for Ruxton – he was hanged at Her Majesty's Prison, Manchester.' The skulls of Isabella and Mary were the recent subject of a BBC appeal by Edinburgh University, who are seeking relatives of the women to finally lay their remains to rest. To hear more horrifying detail about the Ruxton case, search for The Psychology of a Serial Killer. Out now, wherever you get your podcasts.
Hamilton Spectator
2 days ago
- Business
- Hamilton Spectator
Lancaster Resources Clarifies News Release
VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR | OTCQ:LANRF | FRA:6UF0) (the 'Company' or 'Lancaster') is issuing a clarification at the request of the CSE and CIRO concerning the staking of the Lac Iris Polymetallic Project that was previously disclosed as an acquisition. Lancaster is also pleased to provide an update on its properties. The Company's portfolio of projects includes: The Company continues to review gold and critical mineral projects for acquisition. Lac Iris Polymetallic Project Lac Iris is a ~1,443ha project located along the same geological trend as the NISK polymetallic high-grade nickel-copper sulphide deposit. The Lac Iris properties are prospective for polymetallic exploration. Acquisition: The Lac Iris Polymetallic Project was acquired through online staking using Quebec's Mining Title Management system (GESTIM Plus). The titles are currently pending the completion of the provincial mining title review process. Lancaster will provide updates once the review is complete. Lancaster has started collaboration with KorrAI to review opportunities for hyperspectral imaging and a targeted field geological and geochemical program in early fall 2025. The goal of this exploration project is to identify polymetallic and lithium-rich areas/outcroppings, construct detailed geological maps, and evaluate the high-value metals content through rock and soil sampling. Lake Cargelligo Gold Project The Lake Cargelligo Gold project, which encompasses over 28,768 hectares under a single exploration license, features multiple historical high-grade gold and silver occurrences, identified through rock chip and channel sampling, as well as historical drilling. Historical sampling includes results up to 204 g/t Au and 273 g/t Ag from rock chips, and up to 16m @ 5.83 g/t Au and 7.20 g/t Ag from channel sampling.1 Lancaster has initiated local stakeholder discussions to ensure rapid and fulsome approval with both stakeholders and regulatory bodies. This work is expected to complete by mid August 2025 and will allow for Lancaster to initiate its exploration program in Q3 2025. The exploration program will target confirmation of the highly anomalous gold and silver concentrations previously reported. Field geologists will gather rock and soil samples for analysis, along with detailed outcropping and surface geological mapping. In addition, Lancaster will conduct a targeted geophysical program to support follow-up drilling opportunities within the project. The Company has also initiated preparation of a maiden NI 43-101 technical report on the project. Trans-Taiga James Bay Project Lancaster holds the rights to acquire a 100% interest in the Trans-Taiga property located within the James Bay lithium district of Quebec, Canada. Lancaster is reviewing opportunities for a joint field exploration program and HSI data set with the Lac Iris project. This combined effort would save capital and help confirm the significant opportunity at Trans Taiga. Catley Lake & Centennial East Uranium Projects Lancaster holds 100% of the Catley Lake and Centennial East properties in Saskatchewan, Canada. The properties are immediately adjacent to the Cameco Centennial deposit claims. The Cameco Centennial deposit is located just 12 km to the west and has notable uranium concentrations of up to 8.78% U3O8 over 33.9m and 25.6% U3O8 over 0.5m.2 Approximately 24km southwest of Lancaster's claims is the Cameco Dufferin deposit, which has shown assays of up to 1.73% U3O8 over 6.5m. 3 Lancaster's exploration plans include an initial detailed surface outcrop mapping, using hyperspectral data to identify vegetation stress indicative of subsurface uranium, acquiring high-resolution optical imagery, and purchasing corrected imagery for hyperspectral analysis (HSI). Piney Lake Gold Project Lancaster holds 100% of the Piney Lake Gold Property in Saskatchewan, Canada. It is approximately 65 km east of La Ronge Provincial Park and 2.5 km east of North Arrow Minerals' Pikoo property. Historical geochemical samplings for Piney Lake mention significant gold showings identified along a north-south trend. These include concentrations of 7.55g/T Au approximately 375 meters north, and an impressive 41.35g/T Au approximately 4.1km north, among others. 4 Management Commentary 'The Lancaster team is extremely excited about closing our the Lake Cargelligo acquisition. We can now accelerate the development of our precious and critical mineral portfolio by launching exploration programs at Lake Cargelligo and in the James Bay area. With these programs underway, we are focused on delivering significant exploration results and unlocking the discovery potential of both projects', said Lancaster CEO Andrew Watson. All exploration results are historical in nature and have not been verified by a Qualified Person under NI 43-101. The Company considers these results relevant for exploration purposes but not necessarily indicative of mineralization on the property. Management cautions that mineralization hosted on adjacent and/or nearby properties is not necessarily indicative of the presence of similar mineralization or geology on Lancaster's properties. Andrew Watson, President, CEO, and a Director of the Company, is a Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects . Mr. Watson has reviewed and approved the scientific and technical information contained in this news release. Mr. Watson is the President and Chief Executive Officer and a Director of the Company and is not independent of the Company. About Lancaster Resources Inc. Lancaster is focused on building a portfolio of district-scale exploration assets positioned for future resource development. The Company holds a 100% interest in the Piney Lake Gold Project in Saskatchewan, uranium projects at Catley Lake and Centennial East in the Athabasca Basin, and the Lac Iris Polymetallic Project in Quebec's James Bay region, where it also holds an option to acquire the Trans-Taiga property. In Australia, Lancaster owns the Lake Cargelligo Gold Project in New South Wales, covering 28,768 hectares with over 25 km of prospective strike and three primary target zones. Andrew Watson, President & Chief Executive Officer, Lancaster Resources Inc. andrew@ Tel: 604 923 6100 The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release. Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or Lancaster's future performance. The use of any of the words 'could', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Lancaster's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, the ability of Lancaster to execute its exploration plans, raise capital, retain key personnel, identify, acquire, explore, and develop high-quality mineral-rich properties constitutes forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. Lancaster disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws. 1 Sources include: (1) Carpentaria Exploration Ltd., 2014 Annual Report for EL8095; (2) Aberfoyle Exploration Pty Ltd., First and Final Report for EL1770, June 1982; (3) Lachlan Resources N.L., First Six-Month Progress Report for EL2914; and (4) MinView database from the Geological Survey of NSW ( ). 2 . Reports SMDI 2758. 3 . Reports SMDI 74G05-0068. 4 . Reports SMDI 2646 and 2578.
The Sun
4 days ago
- Health
- The Sun
My wife's incurable cancer started with a ‘Mounjaro side effect' – now she's got months left to live
A MUM thought symptoms of her incurable cancer were a side effect of Mounjaro weight loss jabs - now she's been given months to live. Dawn Clegg, 51, began suffering from chest pain in late March this year after taking the jabs to help deal with her diabetes. 10 10 10 The mum eventually went to A&E for her chest pains. She had several X-rays at the hospital, which showed shadows on her lungs, kidneys, and breast. Dawn was later diagnosed with a rare soft-tissue cancer known as sarcoma. She was told the growths on her breast and kidney were benign, but the one on her lungs was sarcoma, which makes up just one per cent of all known cancers. There are more than 100 known sarcomas and Dawn's doctors have been unable to precisely identify the type she has - making treatment challenging. Dawn was given less than a year to live. Now her heartbroken husband Arron Clegg, 51, is planning to hold a "living wake" in November to celebrate the life of his wife. Arron said: "She went to Lancaster Hospital A&E at the end of March with chest pains which she thought were a side effect of Mounjaro which she was taking to help with her diabetes. "X rays showed shadows on lung, kidney and breast. "We were devastated on hearing news of cancer in these areas - there is no cure and she is now terminal. I thought my sore knee was a drunken injury but it was cancer at 27 "The wake will mean she can spend quality time with friends and family whilst still alive rather than after the funeral that way she can see how much people care about her." Dawn, a receptionist with Bay Medical Group who's mum to 19-year-old George, started taking Mounjaro to help with her diabetes. When she noticed tightness in her chest, she initially thought it was a side effect from the jabs. Chest pain isn't a known side effect of Mounjaro, which can cause nausea, vomiting and diarrhoea. 10 In late March, Dawn went to Lancaster Hospital A&E in the hopes of finding out what was causing her chest pain. She had multiple X-rays, which found shadows in her lungs, breasts, and kidney. The next day Dawn was "called back" to hospital where they were informed the growths could be cancerous. Tests which showed the cancer on her breast was benign and her kidney "wasn't a big issue", but she was given the "devastating" news that the cancer on her lungs was sarcoma. The symptoms of sarcoma cancer The most common symptom of soft tissue sarcoma is a lump somewhere on the body. But this doesn't necessarily mean cancer - there are all sorts of reasons for lumps and swellings, but it must always be checked by a GP. The lump is usually found deep under the skin and might be felt before it can be seen. The lump is usually solid to the touch, painless and hard to move around under the skin. It will continue to grow and as it does, it can become painful. Other symptoms depend on where in the body the lump is. These can include: Tummy pain and constipation if there is a sarcoma near the tummy A cough that does not go away if there is a sarcoma near the lungs Source: NHS Sarcoma is a rare type of cancer that develops in the supporting tissues of the body, including bone, cartilage, tendons, fat, and muscle. Arron said: "The doctors don't even know what type of sarcoma it is four months later. "Sarcoma makes up 1 per cent of known cancers and on top of that there are over 100 sarcomas, so finding the right treatment is extremely hard. "She is now terminal and there is a high chance she won't make her fifty-second birthday next year." Dawn began receiving chemotherapy at Clatterbridge in Liverpool but Arron has said "there is more chance of it not working than slowing it down". Following Dawn's diagnosis Arron is now hoping to organise a "living wake" – a joyful celebration of her life surrounded by friends and family while she is still with them. Arron hopes to invited around 100 of his wife's closest family and friends to enjoy a final evening together. Arron said: "Dawn means the world to me. "We went to school together and started dating after we found each other years later and have been married nearly 10 years. 'Dawn is an amazing person; not very patient and yet with this illness she has surprised us both with her patience whilst they tried to find a treatment. "She is the best person I ever knew and the wake will mean the world to her." Arron has started a crowdfunding to help pay for the costs of the wake, which will take place on November 29, and Dawn's funeral. When the time comes, Dawn will be laid to rest near her late daughter Isobel, who died in childbirth. You can visit Arron's GoFundMe here. 10 10 10
